[go: up one dir, main page]
Skip to main content
Springer Nature Link
Log in

Infection-Associated Thrombotic Microangiopathy

  • Chapter
  • First Online:
Bacterial Infections and the Kidney

  • 1126 Accesses

Abstract

The great majority of cases with hemolytic uremic syndrome (HUS) are caused by infections. Over 90% of cases of HUS are caused by infection with various strains of Shiga toxin-producing Escherichia coli bacteria. Invasive infections with Streptococcus pneumoniae account for approximately 40% of Shiga toxin-negative cases. Other infectious agents, including HIV, influenza virus, and several other viral and bacterial pathogens, have also been reported in association with HUS. Infectious causes were among the first recognized etiologies of thrombotic microangiopathy (TMA), which are the main focus of this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

eBook
USD 12.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr. 1955;85(38–39):905–9.

    CAS  PubMed  Google Scholar 

  2. Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis. 2004;43(6):976–82.

    Article  PubMed  Google Scholar 

  3. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654–66.

    Article  CAS  PubMed  Google Scholar 

  4. Russo P, Doyon J, Sonsino E, Ogier H, Saudubray JM. A congenital anomaly of vitamin B12 metabolism: a study of three cases. Hum Pathol. 1992;23(5):504–12.

    Article  CAS  PubMed  Google Scholar 

  5. Geraghty MT, Perlman EJ, Martin LS, Hayflick SJ, Casella JF, Rosenblatt DS, et al. Cobalamin C defect associated with hemolytic-uremic syndrome. J Pediatr. 1992;120(6):934–7.

    Article  CAS  PubMed  Google Scholar 

  6. Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis. 2014;63(1):119–23.

    Google Scholar 

  7. Galbusera M, Noris M, Remuzzi G. Thrombotic thrombocytopenic purpura–then and now. Semin Thromb Hemost. 2006;32(2):81–9.

    Article  PubMed  Google Scholar 

  8. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116(20):4060–9.

    Article  CAS  PubMed  Google Scholar 

  9. Nguyen TC, Han YY. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis. 2011;7(1):28–31.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kurosawa S, Stearns-Kurosawa DJ. Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care. 2014;2(1):65.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006;70(3):423–31.

    Article  CAS  PubMed  Google Scholar 

  12. Katoh M, Shigematsu H. Renal involvement of thrombotic thrombocytopenic purpura: special reference to the glomeruloid structures. Pathol Int. 1999;49(7):638–42.

    Article  CAS  PubMed  Google Scholar 

  13. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985;38(5):469–79.

    Article  CAS  PubMed  Google Scholar 

  14. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983;308(12):681–5.

    Article  CAS  PubMed  Google Scholar 

  15. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983;1(8325):619–20.

    Article  CAS  PubMed  Google Scholar 

  16. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985;151(5):775–82.

    Article  CAS  PubMed  Google Scholar 

  17. Bell BP, Goldoft M, Griffin PM, Davis MA, Gordon DC, Tarr PI, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA. 1994;272(17):1349–53.

    Article  CAS  PubMed  Google Scholar 

  18. Akashi S, Joh K, Tsuji A, Ito H, Hoshi H, Hayakawa T, et al. A severe outbreak of haemorrhagic colitis and haemolytic uraemic syndrome associated with Escherichia coli O157:H7 in Japan. Eur J Pediatr. 1994;153(9):650–5.

    Article  CAS  PubMed  Google Scholar 

  19. Fukushima H, Hashizume T, Morita Y, Tanaka J, Azuma K, Mizumoto Y, et al. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996. Pediatr Int. 1999;41(2):213–7.

    Article  CAS  PubMed  Google Scholar 

  20. Piercefield EW, Bradley KK, Coffman RL, Mallonee SM. Hemolytic uremic syndrome after an Escherichia coli O111 outbreak. Arch Intern Med. 2010;170(18):1656–63.

    Article  PubMed  Google Scholar 

  21. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365(19):1771–80.

    Google Scholar 

  22. Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982–2002. Emerg Infect Dis. 2005;11(4):603–9.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Tozzi AE, Caprioli A, Minelli F, Gianviti A, De Petris L, Edefonti A, et al. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988–2000. Emerg Infect Dis. 2003;9(1):106–8.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. J Infect Dis. 2002;186(4):493–500.

    Article  PubMed  Google Scholar 

  25. Tzschoppe M, Martin A, Beutin L. A rapid procedure for the detection and isolation of enterohemorrhagic Escherichia coli (EHEC) serogroup O26, O103, O111, O118, O121, O145 and O157 strains and the aggregative EHEC O104:H4 strain from ready-to-eat vegetables. Int J Food Microbiol. 2012;152(1–2):19–30.

    Article  CAS  PubMed  Google Scholar 

  26. Elliott EJ, Robins-Browne RM, O’Loughlin EV, Bennett-Wood V, Bourke J, Henning P, et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child. 2001;85(2):125–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Johnson KE, Thorpe CM, Sears CL. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin Infect Dis. 2006;43(12):1587–95.

    Article  PubMed  Google Scholar 

  28. Chang HG, Tserenpuntsag B, Kacica M, Smith PF, Morse DL. Hemolytic uremic syndrome incidence in New York. Emerg Infect Dis. 2004;10(5):928–31.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Espie E, Grimont F, Mariani-Kurkdjian P, Bouvet P, Haeghebaert S, Filliol I, et al. Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996–2006. Pediatr Infect Dis J. 2008;27(7):595–601.

    Article  PubMed  Google Scholar 

  30. Cummings KC, Mohle-Boetani JC, Werner SB, Vugia DJ. Population-based trends in pediatric hemolytic uremic syndrome in California, 1994–1999: substantial underreporting and public health implications. Am J Epidemiol. 2002;155(10):941–8.

    Article  PubMed  Google Scholar 

  31. Lathrop S, Edge K, Bareta J. Shiga toxin-producing Escherichia coli, New Mexico, USA, 2004–2007. Emerg Infect Dis. 2009;15(8):1289–91.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Miller DP, Kaye JA, Shea K, Ziyadeh N, Cali C, Black C, et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology. 2004;15(2):208–15.

    Article  PubMed  Google Scholar 

  33. Rahman RC, Cobenas CJ, Drut R, Amoreo OR, Ruscasso JD, Spizzirri AP, et al. Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: retrospective analysis of 54 children. Pediatr Nephrol. 2012;27(2):229–33.

    Article  PubMed  Google Scholar 

  34. Lopez EL, Prado-Jimenez V, O’Ryan-Gallardo M, Contrini MM. Shigella and Shiga toxin-producing Escherichia coli causing bloody diarrhea in Latin America. Infect Dis Clin North Am. 2000;14(1):41–65, viii.

    Google Scholar 

  35. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ. 1999;77(8):651–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Khan WA, Griffiths JK, Bennish ML. Gastrointestinal and extra-intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic. PLoS ONE. 2013;8(5):e64097.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Centers for Disease C, Prevention. Preliminary FoodNet Data on the incidence of infection with pathogens transmitted commonly through food–10 States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(13):333–7.

    Google Scholar 

  38. Hladovec J, Kornalik F. Antithrombotic activity of an unsaturated fatty acid preparation. Thromb Res. 1990;58(5):505–10.

    Article  CAS  PubMed  Google Scholar 

  39. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet. 1998;352(9135):1207–12.

    Article  CAS  PubMed  Google Scholar 

  40. Banatvala N, Griffin PM, Greene KD, Barrett TJ, Bibb WF, Green JH, et al. The United States National prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis. 2001;183(7):1063–70.

    Article  CAS  PubMed  Google Scholar 

  41. Garg AX, Clark WF, Salvadori M, Thiessen-Philbrook HR, Matsell D. Absence of renal sequelae after childhood Escherichia coli O157:H7 gastroenteritis. Kidney Int. 2006;70(4):807–12.

    Article  CAS  PubMed  Google Scholar 

  42. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med. 2002;346(1):23–32.

    Article  CAS  PubMed  Google Scholar 

  43. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. 2003;290(10):1360–70.

    Article  CAS  PubMed  Google Scholar 

  44. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60(3):831–46.

    Article  CAS  PubMed  Google Scholar 

  45. Beatty ME, Griffin PM, Tulu AN, Olsen SJ. Culturing practices and antibiotic use in children with diarrhea. Pediatrics. 2004;113(3 Pt 1):628–9.

    Article  PubMed  Google Scholar 

  46. Ruggenenti P, Remuzzi G. A German outbreak of haemolytic uraemic syndrome. Lancet. 2011;378(9796):1057–8.

    Article  PubMed  Google Scholar 

  47. Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005;115(6):e673–80.

    Article  PubMed  Google Scholar 

  48. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342(26):1930–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA. 2002;288(8):996–1001.

    Article  PubMed  Google Scholar 

  50. Chiurchiu C, Firrincieli A, Santostefano M, Fusaroli M, Remuzzi G, Ruggenenti P. Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection. Am J Kidney Dis. 2003;41(1):E4.

    Article  PubMed  Google Scholar 

  51. Caletti MG, Lejarraga H, Kelmansky D, Missoni M. Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome. Pediatr Nephrol. 2004;19(10):1148–52.

    Article  PubMed  Google Scholar 

  52. Van Dyck M, Proesmans W. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol. 2004;19(6):688–90.

    Article  PubMed  Google Scholar 

  53. Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DW, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA. 2003;290(10):1337–44.

    Article  CAS  PubMed  Google Scholar 

  54. Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WT. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet. 1999;354(9187):1327–30.

    Article  CAS  PubMed  Google Scholar 

  55. Carter AO, Borczyk AA, Carlson JA, Harvey B, Hockin JC, Karmali MA, et al. A severe outbreak of Escherichia coli O157:H7–associated hemorrhagic colitis in a nursing home. N Engl J Med. 1987;317(24):1496–500.

    Article  CAS  PubMed  Google Scholar 

  56. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ. 2012;345:e4565.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, Fiene M, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet. 2011;378(9797):1166–73.

    Article  PubMed  Google Scholar 

  58. Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet. 2011;378(9796):1089–93.

    Article  PubMed  Google Scholar 

  59. Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 2012;27(10):3807–15.

    Article  CAS  PubMed  Google Scholar 

  60. Martin T, Habbick BF, Nyssen J. Shigellosis with bacteremia: a report of two cases and a review of the literature. Pediatr Infect Dis. 1983;2(1):21–6.

    Article  CAS  PubMed  Google Scholar 

  61. Koster F, Levin J, Walker L, Tung KS, Gilman RH, Rahaman MM, et al. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med. 1978;298(17):927–33.

    Article  CAS  PubMed  Google Scholar 

  62. Hawkins C, Taiwo B, Bolon M, Julka K, Adewole A, Stosor V. Shigella sonnei bacteremia: two adult cases and review of the literature. Scand J Infect Dis. 2007;39(2):170–3.

    Article  PubMed  Google Scholar 

  63. Gendrel D, Moreno JL, Nduwimana M, Baribwira C, Raymond J. One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi. Clin Infect Dis. 1997;24(1):83.

    Article  CAS  PubMed  Google Scholar 

  64. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001;32(3):331–51.

    Article  CAS  PubMed  Google Scholar 

  65. D’Agati V, Jennette J, Silva F. Armed Forces Institute of Pathology: non-neoplastic kidney diseases: Armed Forces Institute of Pathology, American Registry of Pathology; 2005.

    Google Scholar 

  66. Koster FT, Boonpucknavig V, Sujaho S, Gilman RH, Rahaman MM. Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clin Nephrol. 1984;21(2):126–33.

    CAS  PubMed  Google Scholar 

  67. Thoenes W, John HD. Endotheliotropic (hemolytic) nephroangiopathy and its various manifestation forms (thrombotic microangiopathy, primary malignant nephrosclerosis, hemolytic-uremic syndrome). Klin Wochenschr. 1980;58(4):173–84.

    Article  CAS  PubMed  Google Scholar 

  68. Morel-Maroger L, Kanfer A, Solez K, Sraer JD, Richet G. Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic-uremic syndrome): clinicopathologic study in 20 adults. Kidney Int. 1979;15(5):548–58.

    Article  CAS  PubMed  Google Scholar 

  69. Taylor CM, Chua C, Howie AJ, Risdon RA. British Association for Paediatric N. Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. Pediatr Nephrol. 2004;19(4):419–25.

    Article  CAS  PubMed  Google Scholar 

  70. Mehrazma M, Hooman N, Otukesh H. Prognostic value of renal pathological findings in children with atypical hemolytic uremic syndrome. Iran J Kidney Dis. 2011;5(6):380–5.

    PubMed  Google Scholar 

  71. Johannes L, Romer W. Shiga toxins–from cell biology to biomedical applications. Nat Rev Microbiol. 2010;8(2):105–16.

    CAS  PubMed  Google Scholar 

  72. Jackson MP, Newland JW, Holmes RK, O’Brien AD. Nucleotide sequence analysis of the structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli. Microb Pathog. 1987;2(2):147–53.

    Article  CAS  PubMed  Google Scholar 

  73. Muthing J, Schweppe CH, Karch H, Friedrich AW. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost. 2009;101(2):252–64.

    PubMed  Google Scholar 

  74. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol. 1999;37(3):497–503.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Fraser ME, Chernaia MM, Kozlov YV, James MN. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat Struct Biol. 1994;1(1):59–64.

    Article  CAS  PubMed  Google Scholar 

  76. Stein PE, Boodhoo A, Tyrrell GJ, Brunton JL, Read RJ. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature. 1992;355(6362):748–50.

    Article  CAS  PubMed  Google Scholar 

  77. Jacewicz M, Clausen H, Nudelman E, Donohue-Rolfe A, Keusch GT. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med. 1986;163(6):1391–404.

    Article  CAS  PubMed  Google Scholar 

  78. Lindberg AA, Brown JE, Stromberg N, Westling-Ryd M, Schultz JE, Karlsson KA. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J Biol Chem. 1987;262(4):1779–85.

    CAS  PubMed  Google Scholar 

  79. Waddell T, Cohen A, Lingwood CA. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc Natl Acad Sci U S A. 1990;87(20):7898–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol. 2006;7(8):568–79.

    Article  CAS  PubMed  Google Scholar 

  81. Johannes L, Popoff V. Tracing the retrograde route in protein trafficking. Cell. 2008;135(7):1175–87.

    Article  CAS  PubMed  Google Scholar 

  82. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988;171(1–2):45–50.

    Article  CAS  PubMed  Google Scholar 

  83. Saxena SK, O’Brien AD, Ackerman EJ. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem. 1989;264(1):596–601.

    CAS  PubMed  Google Scholar 

  84. Hale TL, Formal SB. Cytotoxicity of Shigella dysenteriae 1 for cultured mammalian cells. Am J Clin Nutr. 1980;33(11 Suppl):2485–90.

    CAS  PubMed  Google Scholar 

  85. Iordanov MS, Pribnow D, Magun JL, Dinh TH, Pearson JA, Chen SL, et al. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol. 1997;17(6):3373–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Petruzziello TN, Mawji IA, Khan M, Marsden PA. Verotoxin biology: molecular events in vascular endothelial injury. Kidney Int Suppl. 2009;112:S17–9.

    Article  CAS  Google Scholar 

  87. Matussek A, Lauber J, Bergau A, Hansen W, Rohde M, Dittmar KE, et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood. 2003;102(4):1323–32.

    Article  CAS  PubMed  Google Scholar 

  88. Morigi M, Micheletti G, Figliuzzi M, Imberti B, Karmali MA, Remuzzi A, et al. Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood. 1995;86(12):4553–8.

    CAS  PubMed  Google Scholar 

  89. Zoja C, Angioletti S, Donadelli R, Zanchi C, Tomasoni S, Binda E, et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int. 2002;62(3):846–56.

    Article  CAS  PubMed  Google Scholar 

  90. Zanchi C, Zoja C, Morigi M, Valsecchi F, Liu XY, Rottoli D, et al. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. J Immunol. 2008;181(2):1460–9.

    Article  CAS  PubMed  Google Scholar 

  91. Morigi M, Galbusera M, Binda E, Imberti B, Gastoldi S, Remuzzi A, et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood. 2001;98(6):1828–35.

    Article  CAS  PubMed  Google Scholar 

  92. van Setten PA, Monnens LA, Verstraten RG, van den Heuvel LP, van Hinsbergh VW. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood. 1996;88(1):174–83.

    PubMed  Google Scholar 

  93. Petruzziello-Pellegrini TN, Yuen DA, Page AV, Patel S, Soltyk AM, Matouk CC, et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest. 2012;122(2):759–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187(1):172–80.

    Article  CAS  PubMed  Google Scholar 

  95. Van de Kar NC, Monnens LA, Van Hinsbergh VW. Tumor necrosis factor and interleukin 1 induce expression of the glycolipid verotoxin receptor in human endothelial cells. Implications for the pathogenesis of the haemolytic uraemic syndrome. Behring Inst Mitt. 1993;92:202–9.

    Google Scholar 

  96. Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, Dong JF, et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood. 2005;106(13):4199–209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Liu F, Huang J, Sadler JE. Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways. Blood. 2011;118(12):3392–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Huang J, Haberichter SL, Sadler JE. The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1-dependent manner. Blood. 2012;120(5):1143–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Bolton DJ. Verocytotoxigenic (Shiga toxin-producing) Escherichia coli: virulence factors and pathogenicity in the farm to fork paradigm. Foodborne Pathog Dis. 2011;8(3):357–65.

    Article  CAS  PubMed  Google Scholar 

  100. Nakajima H, Kiyokawa N, Katagiri YU, Taguchi T, Suzuki T, Sekino T, et al. Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J Biol Chem. 2001;276(46):42915–22.

    Article  CAS  PubMed  Google Scholar 

  101. Fuchs G, Mobassaleh M, Donohue-Rolfe A, Montgomery RK, Grand RJ, Keusch GT. Pathogenesis of Shigella diarrhea: rabbit intestinal cell microvillus membrane binding site for Shigella toxin. Infect Immun. 1986;53(2):372–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Banerjee R, Hersh AL, Newland J, Beekmann SE, Polgreen PM, Bender J, et al. Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America. Pediatr Infect Dis J. 2011;30(9):736–9.

    Article  PubMed  Google Scholar 

  103. Cabrera GR, Fortenberry JD, Warshaw BL, Chambliss CR, Butler JC, Cooperstone BG. Hemolytic uremic syndrome associated with invasive Streptococcus pneumoniae infection. Pediatrics. 1998;101(4 Pt 1):699–703.

    Article  CAS  PubMed  Google Scholar 

  104. McGraw ME, Lendon M, Stevens RF, Postlethwaite RJ, Taylor CM. Haemolytic uraemic syndrome and the Thomsen Friedenreich antigen. Pediatr Nephrol. 1989;3(2):135–9.

    Article  CAS  PubMed  Google Scholar 

  105. Nathanson S, Deschenes G. Prognosis of Streptococcus pneumoniae-induced hemolytic uremic syndrome. Pediatr Nephrol. 2001;16(4):362–5.

    Article  CAS  PubMed  Google Scholar 

  106. Bender JM, Ampofo K, Byington CL, Grinsell M, Korgenski K, Daly JA, et al. Epidemiology of Streptococcus pneumoniae-induced hemolytic uremic syndrome in Utah children. Pediatr Infect Dis J. 2010;29(8):712–6.

    Article  PubMed  Google Scholar 

  107. Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience. J Pediatr. 2007;151(2):140–4.

    Article  PubMed  Google Scholar 

  108. Copelovitch L, Kaplan BS. Streptococcus pneumoniae—associated hemolytic uremic syndrome: classification and the emergence of serotype 19A. Pediatrics. 2010;125(1):e174–82.

    Article  PubMed  Google Scholar 

  109. Kaplan SL, Barson WJ, Lin PL, Stovall SH, Bradley JS, Tan TQ, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429–36.

    Article  PubMed  Google Scholar 

  110. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196(9):1346–54.

    Article  PubMed  Google Scholar 

  111. Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016–27.

    Article  PubMed  Google Scholar 

  112. Balaji V, Jayaraman R, Verghese VP, Baliga PR, Kurien T. Pneumococcal serotypes associated with invasive disease in under five children in India & implications for vaccine policy. Indian J Med Res. 2015;142(3):286–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Duvvuri VR, Deng X, Teatero S, Memari N, Athey T, Fittipaldi N, et al. Population structure and drug resistance patterns of emerging non-PCV-13 Streptococcus pneumoniae serotypes 22F, 15A, and 8 isolated from adults in Ontario, Canada. Infect Genet Evol. 2016;42:1–8.

    Article  CAS  PubMed  Google Scholar 

  114. Andrade AL, Minamisava R, Policena G, Cristo EB, Domingues CM, de Cunto Brandileone MC, et al. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: a time-series analysis. Hum Vaccin Immunother. 2016;12(2):285–92.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Ceyhan M, Ozsurekci Y, Gurler N, Oksuz L, Aydemir S, Ozkan S, et al. Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008–2014. Hum Vaccin Immunother. 2016;12(2):308–13.

    Article  PubMed  Google Scholar 

  116. Chang Q, Stevenson AE, Croucher NJ, Lee GM, Pelton SI, Lipsitch M, et al. Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced. BMC Infect Dis. 2015;15:68.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Golden AR, Adam HJ, Gilmour MW, Baxter MR, Martin I, Nichol KA, et al. Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011–13. J Antimicrob Chemother. 2015;70(7):1960–4.

    CAS  PubMed  Google Scholar 

  118. Klein PJ, Bulla M, Newman RA, Muller P, Uhlenbruck G, Schaefer HE, et al. Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome. Lancet. 1977;2(8046):1024–5.

    Article  CAS  PubMed  Google Scholar 

  119. Novak RW, Martin CR, Orsini EN. Hemolytic-uremic syndrome and T-cryptantigen exposure by neuraminidase-producing pneumococci: an emerging problem? Pediatr Pathol. 1983;1(4):409–13.

    Article  CAS  PubMed  Google Scholar 

  120. Eder AF, Manno CS. Does red-cell T activation matter? Br J Haematol. 2001;114(1):25–30.

    Article  CAS  PubMed  Google Scholar 

  121. Szilagyi A, Kiss N, Bereczki C, Talosi G, Racz K, Turi S, et al. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant. 2013;28(9):2237–45.

    Article  CAS  PubMed  Google Scholar 

  122. Boccia RV, Gelmann EP, Baker CC, Marti G, Longo DL. A hemolytic-uremic syndrome with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101(5):716–7.

    Article  CAS  PubMed  Google Scholar 

  123. Centers for Disease C. Update on acquired immune deficiency syndrome (AIDS)—United States. MMWR Morb Mortal Wkly Rep. 1982;31(37):507–8, 13–4.

    Google Scholar 

  124. Marx JL. Strong new candidate for AIDS agent. Science. 1984;224(4648):475–7.

    Article  CAS  PubMed  Google Scholar 

  125. Chu QD, Medeiros LJ, Fisher AE, Chaquette RF, Crowley JP. Thrombotic thrombocytopenic purpura and HIV infection. South Med J. 1995;88(1):82–6.

    Article  CAS  PubMed  Google Scholar 

  126. Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood. 1992;80(8):1890–5.

    CAS  PubMed  Google Scholar 

  127. Ucar A, Fernandez HF, Byrnes JJ, Lian EC, Harrington WJ Jr. Thrombotic microangiopathy and retroviral infections: a 13-year experience. Am J Hematol. 1994;45(4):304–9.

    Article  CAS  PubMed  Google Scholar 

  128. Sutor GC, Schmidt RE, Albrecht H. Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of the literature. Infection. 1999;27(1):12–5.

    Article  CAS  PubMed  Google Scholar 

  129. Becker S, Fusco G, Fusco J, Balu R, Gangjee S, Brennan C, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis. 2004;39(Suppl 5):S267–75.

    Article  PubMed  Google Scholar 

  130. Gervasoni C, Ridolfo AL, Vaccarezza M, Parravicini C, Vago L, Adorni F, et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis. 2002;35(12):1534–40.

    Article  PubMed  Google Scholar 

  131. Pene F, Vigneau C, Auburtin M, Moreau D, Zahar JR, Coste J, et al. Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Med. 2005;31(1):71–8.

    Article  PubMed  Google Scholar 

  132. Outschoorn UM, Ferber A. Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study. Am J Hematol. 2006;81(12):895–900.

    Article  PubMed  Google Scholar 

  133. Benjamin M, Terrell DR, Vesely SK, Voskuhl GW, Dezube BJ, Kremer Hovinga JA, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis. 2009;48(8):1129–37.

    Article  PubMed  Google Scholar 

  134. Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura–favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011;153(4):515–9.

    Article  CAS  PubMed  Google Scholar 

  135. Francois A, Dhib M, Dubois D, Fillastre JP, Hemet J. Thrombotic microangiopathy (TMA) as the first manifestation of HIV infection. Clin Nephrol. 1993;39(6):352–4.

    CAS  PubMed  Google Scholar 

  136. Sacristan Lista F, Saavedra Alonso AJ, Oliver Morales J, Vazquez Martul E. Nephrotic syndrome due to thrombotic microangiopathy (TMA) as the first manifestation of human immunodeficiency virus infection: recovery before antiretroviral therapy without specific treatment against TMA. Clin Nephrol. 2001;55(5):404–7.

    Google Scholar 

  137. Badesha PS, Saklayen MG. Hemolytic uremic syndrome as a presenting form of HIV infection. Nephron. 1996;72(3):472–5.

    Article  CAS  PubMed  Google Scholar 

  138. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488–94.

    Article  CAS  PubMed  Google Scholar 

  139. Gunther K, Garizio D, Nesara P. ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura. Transfusion. 2007;47(9):1710–6.

    Article  PubMed  Google Scholar 

  140. Malak S, Wolf M, Millot GA, Mariotte E, Veyradier A, Meynard JL, et al. Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity. Scand J Immunol. 2008;68(3):337–44.

    Article  CAS  PubMed  Google Scholar 

  141. Saab KR, Elhadad S, Copertino D, Laurence J. Thrombotic microangiopathy in the setting of HIV infection: a case report and review of the differential diagnosis and therapy. AIDS Patient Care STDS. 2016;30(8):359–64.

    Article  PubMed  Google Scholar 

  142. Jin A, Boroujerdi-Rad L, Shah G, Chen JL. Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab. Clin Kidney J. 2016;9(4):576–9.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Kosugi N, Tsurutani Y, Isonishi A, Hori Y, Matsumoto M, Fujimura Y. Influenza A infection triggers thrombotic thrombocytopenic purpura by producing the anti-ADAMTS13 IgG inhibitor. Intern Med. 2010;49(7):689–93.

    Article  PubMed  Google Scholar 

  144. Farinha A, Carrilho P, Felgueiras J, Natario A, Assuncao J, Vinhas J. Haemolytic uraemic syndrome associated with H1N1 influenza. NDT Plus. 2010;3(5):447–8.

    PubMed  PubMed Central  Google Scholar 

  145. Akiyama R, Komori I, Hiramoto R, Isonishi A, Matsumoto M, Fujimura Y. H1N1 influenza (swine flu)-associated thrombotic microangiopathy with a markedly high plasma ratio of von Willebrand factor to ADAMTS13. Intern Med. 2011;50(6):643–7.

    Article  PubMed  Google Scholar 

  146. Yang Y, Tang H. Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia. Cell Mol Immunol. 2016;13(4):432–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Jonsson MK, Hammenfors D, Oppegaard O, Bruserud O, Kittang AO. A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis. 2015;26(4):469–72.

    Article  PubMed  Google Scholar 

  148. Tsujii N, Nogami K, Yoshizawa H, Hayakawa M, Isonishi A, Matsumoto M, et al. Influenza-associated thrombotic microangiopathy with unbalanced von Willebrand factor and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 levels in a heterozygous protein S-deficient boy. Pediatr Int. 2016;58(9):926–9.

    Article  PubMed  Google Scholar 

  149. Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? J Clin Apher. 2007;22(1):21–5.

    Article  PubMed  Google Scholar 

  150. Douglas KW, Pollock KG, Young D, Catlow J, Green R. Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience. J Clin Apher. 2010;25(2):47–53.

    PubMed  Google Scholar 

  151. Java A, Edwards A, Rossi A, Pandey R, Gaut J, Delos Santos R, et al. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int. 2015;28(9):1121–5.

    Article  PubMed  PubMed Central  Google Scholar 

  152. Lopes da Silva R. Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther. 2011;4(2):51–9.

    Google Scholar 

  153. Inagaki N, Sugimoto K, Hosone M, Isobe Y, Yamamoto Y, Sasaki M, et al. Disseminated Mucor infection and thrombotic microangiopathy in lymphoma-associated hemophagocytic syndrome. Int J Hematol. 2008;88(3):355–6.

    Article  PubMed  Google Scholar 

  154. Peterson EA, Gerrie AS, Power MM, Poulin MP, Dalal BI, Forrest DL. Disseminated mucormycosis presenting as transplant-associated thrombotic microangiopathy. Leuk Res. 2011;35(7):e138–40.

    Article  PubMed  Google Scholar 

  155. Grigg A, Clouston D. Disseminated fungal infection and early onset microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15(5):795–7.

    CAS  PubMed  Google Scholar 

  156. Rahbar A, Soderberg-Naucler C. Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation. J Virol. 2005;79(4):2211–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, California, 94143, USA

    Anatoly Urisman & Zoltan G. Laszik

Authors
  1. Anatoly Urisman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zoltan G. Laszik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anatoly Urisman .

Editor information

Editors and Affiliations

  1. Renal and Transplant Pathology Laboratory, Department of Pathology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA

    Anjali A. Satoskar

  2. Renal and Transplant Pathology Laboratory, Department of Pathology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA

    Tibor Nadasdy

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Urisman, A., Laszik, Z.G. (2017). Infection-Associated Thrombotic Microangiopathy. In: Satoskar, A., Nadasdy, T. (eds) Bacterial Infections and the Kidney. Springer, Cham. https://doi.org/10.1007/978-3-319-52792-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52792-5_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52790-1

  • Online ISBN: 978-3-319-52792-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics